Regeneron Pharmaceuticals, Inc. $REGN Stake Boosted by Park Avenue Securities LLC

Park Avenue Securities LLC lifted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 79.7% in the 3rd quarter, Holdings Channel.com reports. The firm owned 2,809 shares of the biopharmaceutical company’s stock after purchasing an additional 1,246 shares during the period. Park Avenue Securities LLC’s holdings in Regeneron Pharmaceuticals were worth $2,130,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of REGN. BlackRock Inc. acquired a new position in shares of Regeneron Pharmaceuticals during the second quarter worth $5,682,636,000. Legal & General Group Plc acquired a new stake in Regeneron Pharmaceuticals in the second quarter valued at $473,872,000. Bank of New York Mellon Corp acquired a new stake in Regeneron Pharmaceuticals in the second quarter valued at $472,950,000. Deutsche Bank AG purchased a new stake in Regeneron Pharmaceuticals during the 2nd quarter worth about $323,249,000. Finally, Man Group plc purchased a new stake in Regeneron Pharmaceuticals during the 2nd quarter worth about $272,460,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Stock Performance

Shares of Regeneron Pharmaceuticals stock opened at $927.89 on Friday. The firm’s fifty day simple moving average is $793.30 and its 200-day simple moving average is $738.05. The stock has a market capitalization of $95.54 billion, a price-to-earnings ratio of 20.49, a PEG ratio of 1.57 and a beta of 0.16. Regeneron Pharmaceuticals, Inc. has a 12 month low of $591.52 and a 12 month high of $935.35. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.34 and a quick ratio of 2.78.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 earnings per share for the quarter, beating the consensus estimate of $16.51 by $3.56. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The business had revenue of $5.12 billion for the quarter, compared to the consensus estimate of $4.58 billion. During the same quarter in the previous year, the firm earned $11.83 earnings per share. The business’s quarterly revenue was up 36.3% compared to the same quarter last year. As a group, equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 49.10 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts have recently issued reports on the company. Piper Sandler upped their price objective on Regeneron Pharmaceuticals from $854.00 to $865.00 and gave the stock an “overweight” rating in a research report on Monday, October 19th. Weiss Ratings reissued a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research report on Monday, September 21st. Benchmark raised Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 target price on the stock in a research report on Tuesday, July 7th. Citigroup boosted their target price on Regeneron Pharmaceuticals from $740.00 to $825.00 and gave the stock a “neutral” rating in a research note on Friday. Finally, The Goldman Sachs Group upped their price target on Regeneron Pharmaceuticals from $965.00 to $972.00 and gave the company a “buy” rating in a report on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and eight have issued a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $850.83.

Regeneron Pharmaceuticals News Summary

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Q3 earnings and revenue beat expectations: Regeneron reported $5.12 billion in revenue, up 36.3% year over year and well above the approximately $4.56 billion analyst consensus. Non-GAAP EPS was $20.07, compared with estimates near $16.42 and $11.83 a year earlier. REGN Q3 Earnings Beat on Dupixent Profits & Eylea HD Growth, Stock Up
• Positive Sentiment: Strong commercial performance: Sanofi-partnered Dupixent generated robust demand, while U.S. Eylea HD sales increased 62% to $699 million and global Libtayo sales rose 51% to $550 million. The results suggest Regeneron’s product portfolio is offsetting competitive and pricing pressures in older treatments. Regeneron Reports Third Quarter 2026 Financial and Operating Results
• Positive Sentiment: Pipeline and strategic momentum: Regeneron highlighted progress toward upcoming FDA catalysts, expanded its Sanofi collaboration with next-generation long-acting immunology antibodies and received a $1 billion upfront payment to be recognized as collaboration revenue. A new Phase 2 cemiplimab combination study also expands its skin-cancer pipeline. Regeneron Expands Skin Cancer Pipeline With New Cemiplimab Combo Trial
• Neutral Sentiment: Management characterized 2026 as potentially one of Regeneron’s strongest years, and analysts have raised some expectations following the earnings beat. Investors will now focus on whether Dupixent growth and new launches can remain durable.
• Negative Sentiment: Eylea 2 mg remains exposed to biosimilar competition, while at least one analyst recently lowered Regeneron’s price target from $900 to $850. After the sharp upward move, valuation and the need for continued execution could create near-term volatility. Evercore ISI Adjusts Price Target on Regeneron Pharmaceuticals

Insider Activity

In related news, Director Kathryn Guarini sold 400 shares of the company’s stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $850.00, for a total transaction of $340,000.00. Following the completion of the transaction, the director owned 603 shares of the company’s stock, valued at approximately $512,550. This represents a 39.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marion Mccourt sold 1,215 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $850.00, for a total transaction of $1,032,750.00. Following the transaction, the executive vice president directly owned 13,134 shares in the company, valued at approximately $11,163,900. This trade represents a 8.47% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 8,093 shares of company stock worth $6,506,845. 6.97% of the stock is currently owned by corporate insiders.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.